1. Introduction {#sec1}
===============

Influenza vaccination in the community can significantly reduce influenza infection \[[@B1]\] and incidence of influenza-like illness among the elderly \[[@B2]\], as well as hospitalization and death due to pneumonia, influenza \[[@B3]--[@B7]\], or cardiovascular diseases \[[@B1], [@B3]--[@B8]\]. Furthermore, randomized controlled studies have demonstrated benefits in reducing major adverse cardiovascular events among patients with coronary artery diseases (CAD) \[[@B9]--[@B13]\]. For this reason, the American Heart Association and American College of Cardiology recommend influenza vaccination as a secondary prevention intervention in patients with CAD and atherosclerotic vascular diseases \[[@B14], [@B15]\] and those with ST-segment elevation myocardial infarction (STEMI) \[[@B16]\] and unstable angina/non-STEMI \[[@B17]\] as well as a plan of care for patients with chronic heart failure \[[@B18]\].

Nonetheless, the evidence-based recommendations and benefits of influenza vaccination have been shown in CAD; the mechanisms of its benefit have not yet been defined, as well as some queries on the vaccine immunological response in patients with various clinical characteristics, such as impaired renal function or concurrent medications \[[@B19]--[@B22]\]. The study of prognostic indicators and patients\' clinical characteristics may describe the benefits of influenza vaccine for cardiovascular outcomes.

An annual influenza vaccination can prevent influenza virus infection and relieve the symptoms of acute infection. In fact, an annual influenza vaccination can prevent influenza infection and also decrease the results from acute infection, where it promotes inflammation and the progression of atherosclerosis and it serves as a trigger for acute myocardial infarction \[[@B23]--[@B29]\]. Consequently, the administration of influenza vaccine may reveal an influence on some prognostic indicators for cardiovascular outcomes, compared with patients not receiving the vaccination.

Therefore, this study aimed to explore the effects of the influenza vaccine through the prognostic indicators for each cardiovascular outcome among ACS patients.

2. Patients and Methods {#sec2}
=======================

2.1. Data Sources and Data Collection {#sec2.1}
-------------------------------------

This observational study was based on a prospective, randomized open with blinded endpoint study from Phrommintikul et al. \[[@B9]\], which enrolled 439 patients who had been admitted due to ACS and were older than 50 years old. Patients were excluded if they had hemoglobin level lower than 10 g/dL, elevated serum creatinine (SCr) level more than 2.5 mg/dL, well-established liver disease, cancer or life expectancy less than one year, and contraindications to, or previous, influenza vaccination. All patients were given standard treatment by their primary cardiologist in the tertiary care hospital of Chiang Mai University.

2.2. Definition {#sec2.2}
---------------

The ACS patients were classified into three groups. These included the following: (1) patients with an acute ST-segment elevation myocardial infarction (STEMI) described as a chest pain lasting longer than 20 minutes with ST-segment elevation of electrocardiograph (EKG) in two consecutive leads or more, (2) patients with chest pain lasting longer than 20 minutes, with rising of cardiac troponin or CK-MB and without ST-segment elevation EKG, defined as non-ST-segment elevation myocardial infarction (NSTEMI), and (3) patients with chest pain at rest without rising of cardiac troponin or CK-MB, diagnosed as an unstable angina (UA), whereas NSTEMI and UA were defined as non-ST-segment elevation ACS (NSTE-ACS).

The studied patients\' characteristics included age, sex, concurrent comorbidities, that is, hypertension (HT); diabetes mellitus (DM); dyslipidemia; chronic obstructive pulmonary disease (COPD); smoking; prior myocardial infarction (MI); chronic kidney disease (CKD), SCr, type of ACS, revascularization procedure, left ventricular ejection fraction (LVEF), and medications.

The main cardiovascular outcomes of interest were defined as (1) major adverse cardiovascular events (MACEs), a composite of all cardiovascular events, (2) all causes of mortality, (3) hospitalization due to acute coronary syndrome (ACS), (4) hospitalization due to heart failure (HF), and (5) composite outcomes of hospitalization (ACS, HF, or stroke). These outcomes were verified by cardiologists during the follow-up of 12 months. Survival status of patients lost to follow-up was determined by telephone.

2.3. Data Analysis {#sec2.3}
------------------

The patients\' characteristics were compared among five types of adverse cardiovascular outcomes and each outcome-free group, using Fisher\'s exact test, where multiple imputations were manipulated for missing data management.

Prognostic indicators for each cardiovascular outcome were stratified by influenza vaccine groups and analyzed as multivariable hazard ratio by the stratified Cox regression.

The *Z*-test was performed to demonstrate significant discrimination of hazard ratio between influenza vaccination groups \[[@B30]\].

Multivariable Cox\'s regression was conducted to present the results, subsequently adjusted for independent prognostic indicators of each cardiovascular outcome.

This study was approved by the Ethics Committee, Faculty of Medicine, Chiang Mai University.

3. Results {#sec3}
==========

3.1. Patients\' Characteristics {#sec3.1}
-------------------------------

In this observational study, data of 439 ACS patients were collected. Half of the patients were older than 65 years old and 56.7% of the patients (249) were males ([Table 1](#tab1){ref-type="table"}). HT was present among 265 (60.4%); DM, 134 (30.5%); dyslipidemia, 206 (46.9%); COPD, 13 (3.0%); and CKD, 20 (4.56%). Regarding the index ACS, STEMI and NSTE-ACS were present among 159 (36.2%) and 280 (63.8%) of the patients, respectively. The majority of STEMI patients (79.25%) received reperfusion therapy and more than a half of the NSTE-ACS patients (53.21%) received coronary revascularization. Aspirin, beta-blockers, and statin were received among 427 (97.3%), 325 (74.0%), and 293 (66.7%) patients, respectively.

3.2. Prognostic Indicators of Adverse Outcomes {#sec3.2}
----------------------------------------------

The characteristics of ACS patients with and without MACEs were not significantly different, except for dyslipidemia, LVEF, receiving angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), and influenza vaccination ([Table 1](#tab1){ref-type="table"}). Patients with MACEs had higher proportion of dyslipidemia (61.3% versus 44.6%, *P* = 0.019) but a lower proportion of receiving ACE-I/ARB (45.2% versus 60.7%, *P* = 0.026) and influenza vaccination (33.9% versus 53.1%, *P* = 0.006). The MACEs-free patients also had a great proportion of preserved LVEF (LVEF \> 40%) (70.8% versus 51.6%, *P* = 0.005) ([Table 1](#tab1){ref-type="table"}).

Regarding the causes of death, patients who survived were younger (age 65 ± 9.17 versus 73.0 ± 9.29 years, *P* = 0.0014). The other clinical characteristics did not significantly differ between two groups ([Table 1](#tab1){ref-type="table"}).

When comparing between patients with composite outcomes of hospitalization due to ACS, HF, or stroke and those who were not hospitalized ([Table 2](#tab2){ref-type="table"}), patients with these events had a higher proportion of dyslipidemia (63.3% versus 44.9%, *P* = 0.022) and impaired LVEF (LVEF \< 40%) (49.0% versus 29.7%, *P* = 0.009). They also had low proportion of influenza vaccination (32.7% versus 52.6%, *P* = 0.010) ([Table 2](#tab2){ref-type="table"}).

The comparison of three outcomes among those hospitalized due to ACS, HF, and event-free patients revealed significant differences in proportion of dyslipidemia (58.9%, 78.6%, and 44.8%, resp., *P* = 0.017), CKD (2.9%, 28.6%, and 3.8%, resp., *P* = 0.004), impaired LVEF (35.3%, 78.6%, and 29.9%, resp., *P* = 0.001), and influenza vaccination (32.35%, 28.57%, and 52.69%, resp., *P* = 0.020) ([Table 2](#tab2){ref-type="table"}). Interestingly, patients hospitalized due to HF had a high proportion of dyslipidemia (78.6%, *P* = 0.017), presented CKD (28.6%, *P* = 0.004), and impaired LVEF (78.6%, *P* = 0.001) but revealed a lower proportion of receiving influenza vaccination (28.6%, *P* = 0.020).

When stratified Cox\'s regression analysis by influenza vaccine group was performed for each cardiovascular outcome ([Table 3](#tab3){ref-type="table"}), the significant protective indicator was receiving ACE-I/ARB, while impaired LVEF, age above 65 years, and CKD presented poor indicators in the nonvaccination group.

The impaired LVEF variables were shown as poor prognostic indicators in both groups of patients with similar hazard ratios (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}). Age above 65 years was indicated as a significant prognostic indicator for death in the nonvaccination group (HR = 10.78, 95% CI = 1.39--83.62, *P* = 0.023) but not in the vaccination group (HR = 2.28, 95% CI = 0.42--12.48, *P* = 0.341). However, the effect size of age did not significantly vary between vaccination groups (*P* = 0.252) ([Table 4](#tab4){ref-type="table"}). Differently, the CKD variable was a promising poor prognostic indicator in both groups, (HR = 5.12, 95% CI = 1.27--20.65, *P* = 0.022) and (HR = 24.01, 95% CI = 1.34--417.20, *P* = 0.029). However, the effect size of CKD hazard ratio seemed to diverge with a wide range of confidence intervals; a significant difference was not demonstrated (*P* = 0.340) ([Table 4](#tab4){ref-type="table"}).

Receiving beta-blockers was shown as a nonprotective indicator as well as demonstrating no prognostic value in the nonvaccination group, but it was shown as a potential protective indicator in the vaccination group (HR = 0.05, 95% CI = 0.003--0.76, *P* = 0.037) ([Table 3](#tab3){ref-type="table"}). Moreover, the comparison of hazard ratio between vaccination groups indicated a remarkable difference (*P* = 0.03) ([Table 4](#tab4){ref-type="table"}).

In summary, the influenza vaccination influenced the prognostic value of clinical predictors for each cardiovascular outcome when compared with nonvaccination group, except two predictors of impaired LVEF for MACEs (HR = 2.07, 95% CI = 1.12--3.82, *P* = 0.021 and HR = 2.37, 95% CI = 1.01--5.59, *P* = 0.048) and CKD for hospitalization due to HF (HR = 5.12, 95% CI = 1.27--20.65, *P* = 0.022 and HR = 24.01, 95% CI = 1.34--417.20, *P* = 0.029). However, no significant difference was observed of hazard ratios between influenza vaccination groups, but receiving beta-blockers revealed the differences (*P* = 0.030) ([Table 4](#tab4){ref-type="table"}).

Multivariable Cox\'s regression ([Table 5](#tab5){ref-type="table"}) demonstrated that influenza vaccination and beta-blockers coadministration indicated a potential protective effect (HR = 0.05, 95% CI = 0.004--0.71, *P* = 0.027) after adjusting for sex, dyslipidemia, CKD, SCr, and LVEF, but both factors were independent prognostic indicators for hospitalization due to HF.

The interaction of influenza vaccination among patients receiving beta-blockers was described by a significant reduction of the hazard ratio among patients who had vaccination. This protective interaction showed benefits of receiving influenza vaccination with beta-blocker for hospitalization due to HF among ACS patients.

4. Discussion {#sec4}
=============

This post hoc study demonstrated that the significant prognostic indicators for cardiovascular events in patients with ACS were age, LVEF, CKD, and receiving ACE-I/ARB. Even though the hazard ratio of each individual prognostic factor may differ between the vaccination and nonvaccination groups, the difference was not significant, except for receiving beta-blockers. Receiving beta-blockers presented the prognostic indicator for the reduction of hospitalization due to HF when influenza vaccine was given.

The evidence from seasonal patterns of cardiovascular deaths was similar to patterns of influenza circulation \[[@B29]\]. Clinical findings among patients with influenza presented systemic effects such as myalgia, high fever, and fatigue, as well as frequent myocardial involvement \[[@B29]\]. The influenza virus has extensive effects on the inflammatory and coagulation pathways, leading to destabilization of vulnerable atherosclerotic plaques and coronary occlusion, which are major causes of acute MI \[[@B29]\]. Moreover, host response to acute infections can facilitate ACS by affecting coronary arteries and atherosclerotic lesions, such as increased sympathetic activity \[[@B28]\].

The upregulated sympathetic nervous system shown in heart failure \[[@B18]\] may reduce the influenza vaccine response \[[@B32]--[@B34]\] or cause persistence decline of antibody titers \[[@B33]\].

The sympathetic nervous system will increase proinflammatory cytokines and exacerbate influenza infection, as shown in animal models \[[@B35]\]. In the lung of infected animals, the anti-influenza CD8+ T cell response could be limited by sympathetic nervous system \[[@B36]\], while cytotoxic T lymphocytes could effectively respond to different subtypes of influenza A virus with a specific antibody response \[[@B37]\]. Cytotoxic T cells were described as important factors for recovering from influenza infection in humans \[[@B37]\].

Human T and B lymphocytes express beta-2 adrenergic receptors, where the catecholamine effect via beta-2 adrenergic receptors on cytokine regulation decreased responses to vaccines \[[@B38]\]. In contrast, T cell responses were enhanced by the administration of beta-2 adrenergic antagonists \[[@B36]\].

The study in mice showed that acute stress reduced the number of NK cells in the intraparenchymal region of the lungs and this event could be reversed by the administration of beta-adrenergic antagonists \[[@B39]\]. Acute stress can be hypothesized as the cause of lung lymphocyte redistribution through beta-adrenergic stimulation by elevating catecholamine level \[[@B39]\]. Therefore, beta-blockers could reduce the inflammatory response and the degree of lung injury. Some animal models revealed survival benefits, particularly when beta-blockers were administered before the septic insult \[[@B40]\].

Beta-blockers are recommended as a secondary prevention for ACS patients recovering from acute MI and without contraindication \[[@B41]\]. ACS was indicated as an important cause of worsening or new-onset of HF and also a common factor precipitating acute decompensated HF \[[@B18]\]. Consequently, prescribing beta-blockers to chronic HF patients is recommended due to their protective results \[[@B18], [@B42]\].

The decrease in heart rate, contractility, and blood pressure due to beta-blockers could inhibit the effects of circulating catecholamines and oxygen demand \[[@B43]\]. Beta-blockers can reduce the sympathetic tone by inhibiting an increase in catecholamine circulation \[[@B44]\], as a cause of proinflammatory cytokines \[[@B35], [@B44]\] and disrupt the immune response \[[@B44]\].

Moreover, the administration of influenza vaccine can prevent influenza infection and also reduce acute infection effects by promoting inflammation, the progression of atherosclerosis, and triggering acute MI \[[@B9]--[@B15], [@B17]\].

In this study, solely administration of beta-blockers or influenza vaccination was not shown to be the protective evidence for hospitalization due to HF among ACS patients. However, the combination of the two showed very synergistic effect during a year of follow-up time.

4.1. Limitation {#sec4.1}
---------------

Incomplete data was a limitation of this study. Only 2 incomplete variables were found from 20 variables. The variables of SCr and LVEF had 6.83% and 54.67% of missing values, respectively. However, multiple imputations were conducted and imputed data were categorized for appropriate data management.

5. Conclusion {#sec5}
=============

The study showed that influenza vaccination influenced the prognostic abilities of clinical predictors for cardiovascular outcomes when compared between patients who received vaccination and the nonvaccination group. However, two predictors of impaired LVEF for MACEs and CKD for hospitalization due to HF were not affected. Moreover, different prognostic ability between influenza vaccination groups was not significantly observed, but receiving beta-blockers was acknowledged.

This study presented the strong modification effect of influenza vaccine among ACS patients who received beta-blockers to reduce hospitalization due to HF. This benefit of influenza vaccination should be noteworthily considered in clinical practice for ACS patients. However, further studies of influenza vaccine and beta-blocker synergy should be established in a larger population involving clinical trials.

Although, this study disclosed a new benefit of influenza vaccine and beta-blockers coadministration in preventing HF hospitalization, a further study involving influenza vaccine among HF patients is strongly recommended.
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###### 

Patients\' characteristics for MACEs and death.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                    Total\        Event-free (A)\   MACEs\       *P* value   Survived\     Death\       *P* value                             
                                     (*n* = 439)   (*n* = 377)       (*n* = 62)               (*n* = 421)   (*n* = 18)                                         
  ---------------------------------- ------------- ----------------- ------------ ----------- ------------- ------------ ----------- ----- ------ ---- ------- -------
  Age (year)                                                                                                                                                    

   ≤65                               219           49.9              194          51.5        25            40.3         0.131       216   51.3   3    16.7    0.006

   \>65                              220           50.1              183          48.5        37            59.7                     205   48.7   15   83.3     

                                                                                                                                                               

  Male                               249           56.7              218          57.8        31            50.0         0.270       243   57.7   6    33.3    0.052

  HT                                 265           60.4              222          58.9        43            69.4         0.126       252   59.9   13   72.2    0.336

  DM                                 134           30.5              113          30.0        21            33.8         0.553       127   30.2   7    38.9    0.440

  Dyslipidemia                       206           46.9              168          44.6        38            61.3         0.019       197   46.8   9    50.0    0.814

  COPD                               13            3.0               11           2.9         2             3.2          1.000       13    3.1    0    0.0     1.000

  Smoking                            48            11.0              45           11.9        3             4.8          0.123       48    11.4   0    0.0     0.241

  Prior MI                           18            4.1               15           4.0         3             4.8          0.729       18    4.3    0    0.0     1.000

  CKD                                20            4.6               15           3.9         5             8.1          0.181       20    4.8    0    0.0     1.000

                                                                                                                                                               

  SCr (mg/dL)                                                                                                                                                   

   ≤1.1                              221           50.3              194          51.5        27            43.6         0.274       212   50.4   9    50.0    1.000

   \>1.1                             218           49.7              183          48.5        35            56.5                     209   49.6   9    50.0     

                                                                                                                                                               

  Type of ACS                                                                                                                                                   

   NSTEMI & UA                       280           63.8              242          64.2        38            61.3         0.671       272   64.6   8    44.4    0.130

   STEMI                             159           36.2              135          35.8        24            38.7                     149   35.4   10   55.6     

                                                                                                                                                               

  Reperfusion or revascularization                                                                                                                              

   No                                164           37.4              141          37.4        23            37.1         1.000       158   37.3   6    33.3    0.808

   Yes                               275           62.6              236          62.6        39            62.9                     263   62.5   12   66.7     

                                                                                                                                                               

  LVEF (%)                                                                                                                                                      

   \>40                              299           68.1              267          70.8        32            51.6         0.005       290   68.9   9    50.0    0.120

   ≤40                               140           31.9              110          29.2        30            48.4                     131   31.1   9    50.0     

                                                                                                                                                               

  Medication                                                                                                                                                    

   Aspirin                           427           97.3              366          97.1        61            98.4         1.000       409   97.2   18   100.0   1.000

    *β*-blocker                      325           74.0              281          74.5        44            71.0         0.536       311   73.9   14   77.8    1.000

   CCB                               72            16.4              63           16.7        9             14.5         0.853       69    16.4   3    16.7    1.000

   ACE-I/ARB                         257           58.5              229          60.7        28            45.2         0.026       250   59.4   7    38.9    0.093

   Statin                            293           66.7              252          66.8        41            66.1         1.000       283   67.2   10   55.6    0.315

   Influenza vaccination             221           50.3              200          53.1        21            33.9         0.006       215   51.1   6    33.3    0.156
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

DM, diabetes mellitus; HT, hypertension; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; CKD, chronic kidney disease; SCr, serum creatinine; ACS, acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; LVEF, left ventricular ejection fraction; CCB, calcium channel blocker; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; MACEs, major adverse cardiovascular events; event-free (A), free events from MACEs.

###### 

Patients\' characteristics of composite outcomes of hospitalization (ACS, HF, or stroke), hospitalization due to ACS, and hospitalization due to HF.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                    Event-free (B)\   Composite hospitalization\   *P* value   Event-free (C)\   Hospitalization due to ACS\   Hospitalization due to HF\   *P* value                            
                                     (*n* = 390)       (*n* = 49)                               (*n* = 391)       (*n* = 34)                    (*n* = 14)                                                        
  ---------------------------------- ----------------- ---------------------------- ----------- ----------------- ----------------------------- ---------------------------- ----------- ---- ------ ---- ------- -------
  Age (year)                                                                                                                                                                                                       

   ≤65                               196               50.3                         23          46.9              0.762                         197                          50.4        17   50.0   5    35.7    0.616

   \>65                              194               49.7                         26          53.1                                            194                          49.6        17   50.0   9    64.3     

                                                                                                                                                                                                                  

  Male                               223               57.2                         26          53.1              0.647                         224                          57.3        20   58.8   5    35.7    0.306

  HT                                 231               59.2                         34          69.4              0.215                         232                          59.3        23   67.7   10   71.4    0.495

  DM                                 116               29.7                         18          36.7              0.326                         116                          29.7        11   32.4   7    50.0    0.242

  Dyslipidemia                       175               44.9                         31          63.3              0.022                         175                          44.8        20   58.8   11   78.6    0.017

  COPD                               11                2.8                          2           4.1               0.646                         12                           3.1         0    0.0    1    7.1     0.286

  Smoking                            45                11.5                         3           6.1               0.335                         45                           11.5        3    8.8    0    0.0     0.491

  Prior MI                           15                3.9                          3           6.1               0.439                         15                           3.8         1    2.9    2    14.3    0.147

  CKD                                15                3.9                          5           10.2              0.060                         15                           3.8         1    2.9    4    28.6    0.004

                                                                                                                                                                                                                  

  SCr (mg/dL)                                                                                                                                                                                                      

   ≤1.1                              201               51.5                         20          40.8              0.174                         202                          51.7        16   47.1   3    21.4    0.077

   \>1.1                             189               48.5                         29          59.2                                            189                          48.3        18   52.9   11   78.6     

                                                                                                                                                                                                                  

  Type of ACS                                                                                                                                                                                                      

   NSTEMI & UA                       247               63.3                         33          37.4              0.639                         248                          63.4        22   64.7   10   71.4    0.907

   STEMI                             143               36.7                         16          32.7                                            143                          36.6        12   35.3   4    28.6     

                                                                                                                                                                                                                  

  Reperfusion or revascularization                                                                                                                                                                                

                                                                                                                                                                                                                  

   No                                146               37.4                         18          36.7              1.000                         146                          37.3        9    26.5   9    64.3    0.054

   Yes                               244               62.6                         31          63.3                                            245                          62.7        25   73.5   5    35.7     

                                                                                                                                                                                                                  

  LVEF (%)                                                                                                                                                                                                         

   \>40                              274               70.3                         25          51.0              0.009                         274                          70.1        22   64.7   3    21.4    0.001

   ≤40                               116               29.7                         24          49.0                                            117                          30.0        12   35.3   11   78.6     

                                                                                                                                                                                                                  

  Medication                                                                                                                                                                                                       

   Aspirin                           379               97.2                         48          98.0              1.000                         380                          97.2        33   97.1   14   100.0   1.000

    *β*-blocker                      291               74.6                         34          69.4              0.489                         291                          74.4        25   73.5   9    64.3    0.676

   CCB                               65                16.7                         7           14.3              0.838                         65                           16.6        5    14.7   2    14.3    1.000

   ACE-I/ARB                         234               60.0                         23          47.0              0.091                         235                          60.1        17   50.0   5    35.7    0.121

   Statin                            259               66.4                         34          69.4              0.749                         260                          66.5        24   70.6   9    64.3    0.872

   Influenza vaccination             205               52.6                         16          32.7              0.010                         206                          52.7        11   32.4   4    28.6    0.020
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DM, diabetes mellitus; HT, hypertension; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; CKD, chronic kidney disease; SCr, serum creatinine; HF, heart failure; ACS, acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; LVEF, left ventricular ejection fraction; CCB, calcium channel blocker; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; Composite hospitalization, composite hospitalization due to ACS, HF, or stroke; event-free (B), free events from composite hospitalization due to ACS, HF, or stroke; event-free (C), free events from hospitalization due to ACS or HF.

###### 

Multivariable hazard ratios stratified by influenza vaccination for each cardiovascular event, which was analyzed by multivariable stratified Cox\'s regression analysis.

  -----------------------------------------------------------------------------------------------------------------------
  Prognostic indicators                                 No vaccination   Influenza vaccination                    
  ----------------------------------------------------- ---------------- ----------------------- ---------------- -------
  MACEs                                                                                                            

   LVEF (%)                                                                                                        

    ≤40                                                 2.07\            0.021                   2.37\            0.048
                                                        (1.12--3.82)                             (1.01--5.59)     

   Medication                                                                                                      

    ACE-I/ARB                                           0.44\            0.012                   1.12\            0.806
                                                        (0.23--0.83)                             (0.45--2.78)     

  Death                                                                                                            

   Age (year)                                                                                                      

    \>65                                                10.78\           0.023                   2.28\            0.341
                                                        (1.39--83.62)                            (0.42--12.48)    

   Medication                                                                                                      

    ACE-I/ARB                                           0.26\            0.041                   1.15\            0.870
                                                        (0.07--0.94)                             (0.21--6.30)     

  Composite hospitalization due to ACS, HF, or stroke                                                              

   LVEF (%)                                                                                                        

    ≤40                                                 2.25\            0.020                   2.16\            0.124
                                                        (1.14--4.45)                             (0.81--5.76)     

   Medication                                                                                                      

    ACE-I/ARB                                           0.48\            0.046                   1.23\            0.701
                                                        (0.24--0.99)                             (0.43--3.54)     

  Hospitalization due to ACS                                                                                       

   No indicator was found                                                                                          

  Hospitalization due to HF                                                                                        

   CKD                                                  5.12\            0.022                   24.01\           0.029
                                                        (1.27--20.65)                            (1.38--417.20)   

   LVEF (%)                                                                                                        

    ≤40                                                 7.93\            0.010                   8.37\            0.090
                                                        (1.63--38.66)                            (0.72--97.72)    

   Medication                                                                                                      

    Beta-blocker                                        1.63\            0.542                   0.05\            0.037
                                                        (0.34--7.78)                             (0.003--0.76)    
  -----------------------------------------------------------------------------------------------------------------------

MACEs, major adverse cardiovascular events; LVEF, left ventricular ejection fraction; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ACS, acute coronary syndrome; HF, heart failure; CKD, chronic kidney disease.

###### 

Discrimination of multivariable hazard ratios by the influenza vaccination for each cardiovascular event.

  ------------------------------------------------------------------------------------------------------------------
  Prognostic indicators                                 No vaccination   Influenza vaccination   *Z*     *P* value
  ----------------------------------------------------- ---------------- ----------------------- ------- -----------
  MACEs                                                                                                   

   LVEF (%)                                                                                               

    ≤40                                                 2.07\            2.37\                   −0.26   0.797
                                                        (1.12--3.82)     (1.01--5.59)                    

   Medication                                                                                             

    ACE-I/ARB                                           0.44\            1.12\                   −1.65   0.098
                                                        (0.23--0.83)     (0.45--2.78)                    

  Death                                                                                                   

   Age (year)                                                                                             

    \>65                                                10.78\           2.28\                   1.14    0.252
                                                        (1.39--83.62)    (0.42--12.48)                   

   Medication                                                                                             

    ACE-I/ARB                                           0.26\            1.15\                   −1.38   0.169
                                                        (0.07--0.94)     (0.21--6.30)                    

  Composite hospitalization due to ACS, HF, or stroke                                                     

   LVEF (%)                                                                                               

    ≤40                                                 2.25\            2.16\                   0.07    0.948
                                                        (1.14--4.45)     (0.81--5.76)                    

   Medication                                                                                             

    ACE-I/ARB                                           0.48\            1.23\                   −1.43   0.152
                                                        (0.24--0.99)     (0.43--3.54)                    

  Hospitalization due to ACS                                                                              

   No indicator was found                                                                                 

  Hospitalization due to HF                                                                               

   CKD                                                  5.12\            24.01\                  −0.95   0.340
                                                        (1.27--20.65)    (1.38--417.20)                  

   LVEF (%)                                                                                               

    ≤40                                                 7.93\            8.37\                   −0.04   0.971
                                                        (1.63--38.66)    (0.72--97.72)                   

   Medication                                                                                             

    Beta-blocker                                        1.63\            0.05\                   2.18    0.030
                                                        (0.34--7.78)     (0.003--0.76)                   
  ------------------------------------------------------------------------------------------------------------------

MACEs, major adverse cardiovascular events; LVEF, left ventricular ejection fraction; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ACS, acute coronary syndrome; HF, heart failure; CKD, chronic kidney disease.

###### 

Multivariable hazard ratios and 95% confidence intervals of influenza vaccination and beta-blocker for hospitalization due to HF.

  Influenza vaccine   Beta-blocker   HR          95% CI        *P* value
  ------------------- -------------- ----------- ------------- -----------
  No                  No             Reference                  
  No                  Yes            1.29        0.27--6.16    0.750
  Yes                 No             2.46        0.40--15.22   0.334
  Yes                 Yes            0.05        0.01--0.71    0.027

*Note*. All analyses were adjusted for gender, dyslipidemia, SCr, and LVEF, which are independent prognostic indicators for hospitalization due to HF.

[^1]: Academic Editor: Mariantonietta Cicoira
